Scientists discover 'legless, headless wonder' that predated the dinosaurs
Paleontologists are marveling over the unique fossil of a marine species that predated the dinosaurs, according to new research.
The fossil, dated to about 444 million years ago, contained a new species of arthropod that fossilized inside-out, earning the description of a "legless, headless wonder," according to a paper published in the journal Palaeontology last week.
MORE: Ancient parasitic 'Venus flytrap' wasp found preserved in amber
The "exceptionally preserved" euarthropod was found with its muscles, sinews, tendons and guts all preserved in "unimaginable detail," said Sarah Gabbott, a professor at the University of Leicester's school of geology and lead author of the paper, said in a statement.
"Remarkably her insides are a mineralised time-capsule," Gabbott said, adding that the specimen's head and legs were lost to decay over hundreds of millions of years.
The new species was dubbed "Keurbos susanae," or "Sue" -- after the mother of the woman who discovered it. Researchers are certain it is primitive marine arthropod, but the precise evolutionary relationships remains "frustratingly elusive," Gabbott said.
The fossil was located on Soom Shale, a band of silts and clays about 250 miles north of Cape Town, South Africa. At the time the strata was laid down, a "devastating" glaciation had wiped out about 85% of Earth's species -- one of the "big five" mass extinctions in Earth's history, the researchers said.
MORE: What scientists learned from a well-preserved fossil of this iconic Jurassic-era species
But the marine basin where Sue was found was somehow protected from the worst of the freezing conditions and provided shelter for a community of "fascinating" species, according to the paper.
"This fossil is just so beautifully preserved there's so much anatomy there that needs interpreting," Gabbott said. "Layer upon on layer of exquisite detail and complexity."
The sediments that trapped the specimen were extremely toxic, the researchers said. The water contained no oxygen, but hydrogen sulphide -- described as not only "stinky" but deadly -- was dissolved in the water, the researchers said.
An unusual chemical alchemy may have been responsible for the unique way Sue was fossilized, the researchers hypothesized.
About 85% of the animals on Earth today are arthropods -- including shrimps, lobsters, spiders, mites, millipedes and centipedes, the paper states.
MORE: How the process of de-extinction will be used to restore this fabled species
The downside to Sue's unique fossilization is it makes it hard to compare the specimen with other fossils of similar species of the time.
"So it remains a mystery how she fits into the evolutionary tree of life," according to the researchers.
Scientists discover 'legless, headless wonder' that predated the dinosaurs originally appeared on abcnews.go.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134登入存取你的投資組合
Yahoo
17 hours ago
- Yahoo
Our planet's oxygen levels will drop, and there's no way to stop it
If you purchase an independently reviewed product or service through a link on our website, BGR may receive an affiliate commission. It's no secret that Earth is doomed. Sure, there's the threat of climate change and the fact that sea levels are rising around the world. But that's not what we're talking about. Instead, our planet's impending doom is actually set to happen billions of years from now, long after we're all gone, when the oxygen levels drop and life as we know it ceases to exist. When this change occurs, it's going to happen pretty rapidly, a study published a few years ago claims. It will be similar to the Great Oxidation Event (GOE) that happened over 2.4 billion years ago. Back then, oxygen flooded the Earth's atmosphere, giving birth to life as we know it today, or at least its earliest evolutionary forms. Today's Top Deals Best deals: Tech, laptops, TVs, and more sales Best Ring Video Doorbell deals Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98 Researchers have long argued that atmospheric oxygen, which humans need to breathe, is unlikely to be a feature of habitable worlds forever. We've seen other planets around us that appear to have been stripped of their oxygen, like Mars and Venus. And many argue that Earth is set to see a similar future at some point down the line. Of course, the factors resulting in dropping oxygen levels are complex. Not only do we have natural global warming to blame, but human-driven climate change could also play a large role in the end of life on Earth as we know it. Models suggest that Earth's oxygen levels could drop as low as those of Archean Earth, when microbial life was the only life to be found on our little blue and green planet. Those levels of oxygen would, obviously, not be ideal for people or animals that require oxygen to breathe. Of course, there is always the chance that we manage to get off Earth and settle somewhere else before Earth becomes uninhabitable, but if we don't, and humans are still alive billions of years from now, then it will be the end of the road. Overall, Earth's future billions of years from now is looking pretty bleak. Scientists estimate that the sun will explode, effectively ending life in our solar system some 2 billion years from now. Before that happens, life on Earth will change drastically, as oxygen levels are expected to drop almost a million times lower than today, researchers told New Scientist. Luckily, the end of the world isn't the most pressing problem we have to face at the moment, though there are arguments about how we could possibly delay the inevitable. Even if we did, there's not really anything we could do about it but hope Elon Musk and NASA's plan to put humans on Mars in the 2030s works out. More Top Deals Amazon gift card deals, offers & coupons 2025: Get $2,000+ free See the
Yahoo
20 hours ago
- Yahoo
Women less likely to get life-saving care for deadly heart condition
A new analysis reveals that women are less likely than men to receive treatment for aortic stenosis, a potentially fatal heart condition. Researchers discovered that women are 11% less likely to be referred to a hospital specialist following a diagnosis of the heart valve disease. Academics noted that the findings reveal "inequities in management and care of this common and serious condition." The study also found differences in care among south Asian and black patients, as well as those from poorer backgrounds. Aortic stenosis, a narrowing of the aortic valve or the area immediately around it, leads to obstruction of the blood flow from the heart, which leads to symptoms including dizziness, fatigue, chest pain and breathlessness. The condition is more common in elderly people. It is not possible to reverse but treatments can include a transcatheter aortic valve implantation (TAVI) or valve replacement surgery. If left untreated it can lead to serious complications, including heart failure, heart rhythm abnormalities, and death. The analysis suggests some people are less likely to receive this treatment. Experts from the University of Leicester examined GP data on 155,000 people diagnosed with aortic stenosis between 2000 and 2022 in England. Presenting their findings to the British Cardiovascular Society conference in Manchester, experts said as well as women being less likely to be referred for hospital care, they are 39% less likely to have a procedure to replace their aortic valve. Researchers also found people living in poorer neighbourhoods are 7% less likely to be referred for hospital care after a diagnosis compared to people from wealthier neighbourhoods. Meanwhile, black patients are 48% less likely to undergo a procedure to replace their aortic valve compared to white patients. South Asian patients are 27% less likely to undergo a procedure compared to their white counterparts, according to the study, which was funded by the National Institute for Health and Care Research (NIHR) and supported by NIHR Leicester Biomedical Research Centre. Dr Anvesha Singh, associate professor at the University of Leicester and consultant cardiologist, who was involved in the research, said: 'Previous studies have shown lower rates of valve replacement in women, and clinicians had assumed that women were less likely to be diagnosed with aortic stenosis. 'This analysis using large, real-world data clearly shows that this is not the case, giving us the clearest picture yet of what is happening in day-to-day clinical practice. 'Our study highlights potential inequities in management and care of this common and serious condition. More research is needed to understand the reasons for this and the true prevalence of aortic stenosis in different groups.' Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, which supported the research, and consultant cardiologist, said: 'This study of over 150,000 GP records has unveiled disparities in access to aortic valve treatment for women, south Asian and black people, and people living in more deprived communities. 'We don't yet have the full picture, but these findings are concerning and we need more research to understand what is driving the differences seen. 'This will be crucial to enable action to address any underlying causes stopping some people from having access to the heart valve treatment and care they need, when they need it.'
